EU drug security talks hit pricing wall

Quick summary

EU member states are deadlocked over the Critical Medicines Act, with Greece and others pushing back against strict requirements to buy from European drugmakers, fearing costs will spike for already-stretched health budgets. The core dispute: how to guarantee medicine supply without pricing out public healthcare systems.

Why it matters

If the EU tightens rules favouring domestic pharmaceutical production, your prescription costs could rise as hospitals pay premiums for European drugs over cheaper imports—affecting both what you pay out-of-pocket and which treatments your national health service can afford to stock.

Key takeaways

• ›Greece is pushing for flexibility in EU preference modules that would allow member states to bypass expensive European manufacturers and buy cheaper alternatives.
• ›The Critical Medicines Act aims to build pharmaceutical resilience after COVID-19 supply chain failures, but creating guaranteed European production capacity requires accepting higher medicine prices.
• ›Health policymakers flagged a core conflict: medicine security and European supply chain independence come at the cost of affordability for cash-strapped EU healthcare systems.
• ›Negotiations are at a critical phase with no resolution on how to balance drug availability guarantees against the pricing pressures facing public health budgets.